Composition
Cap 150 mg/300 mg: Clindamycin (as NCI) 150 mg/300 mg. Syp: Per 5 ml: Clindamycin (as palmitate) 75 mg. lnj 150 mg: Per ml: Clindamycin (as phosphate) 150 mg; amp of 2 ml, 4 ml, 6 ml. Inj 15
Indications & Dosage
Staphylococcal bone and joint infections such as Osteomyelitis, Peritonitis, Intra-abdominal sepsis, Meticillin-resistant Staphylococcus aureus (MRSA) in bronchiectasis, bone and joint infections, and skin and soft-tissue infections, Erysipelas or cellulitis in penicillin-allergic patients: ORAL: Adult: 150-300 mg every 6 hours; increased if necessary up to 450 mg every 6 hours in severe infection; Children: 3-6 mg/kg 4 times a day (max. per dose 450 mg). BY DEEP IM INJ, OR BY IV INF: Adult: 0.6 - 2.7 g daily in 2-4 divided doses; increased if necessary up to 4.8 g daily, increased dose used in life-threatening infection, single doses above 600mg to be administered by IV INF only, not to exceed 1.2 g. Treatment of mild to moderate pneumocystis pneumonia (in combination with primaquine): ORAL: Adult: 600 mg every 8 hours. Treatment of falciparum malaria (to be given with or following quinine): ORAL: Adult: 450 mg every 8 hours for 7 days; Children: 7-13 mg/kg every 8 hours (max. per dose 450 mg) for 7 days. Bacterial Vaginosis: ORAL: Adult (female): 300 mg every 12 hr for 7 days. Septicaemia: BY IV INJ OR IV INF: Adults: 1200-2700 mg/day given in two or four divided doses, up to 4800 mg/day. Children: 1 month-16 yr: 20-40 mg/kg/day given in 3-4 doses; less than1 month: 15-20 mg/ kg/day given 3-4 doses.
Administration
Administer deep IM injection, rotate sites. Do not exceed 600 mg in a single injection. Never give as bolus. Administer by IV intermittent infusion over at least 10-60 min, at a rate not to exceed 30 mg/min; final concentration for administration should not exceed 12 mg/ ml. Dilute 300 mg in 50 ml of diluent and give over 10 mins. Dilute 600 mg in 100 ml of diluent and give over 20 mins. Dilute 900 mg in 100 ml of diluent and give over 30 mins.
Compatibility
Stable in D5LR, D51/2NS, D5NS, D5W, D10W, LR, NS. At Y-site administration, incompatible with allopurinol, filgrastim, fluconazole, idarubicin. In syringe, incompatible with tobramycin. When admixed, incompatible with aminophylline, barbiturates, calcium gluconate, ceftriaxone, ciprofloxacin, gentamicin with cefazolin, magnesium sulphate, phenytoin.
Stability
IV infusion solution in NS or D5W solution is stable for 16 days at room temperature.
Contraindications
Lincosamide sensitivity.
Precautions
Renal or hepatic impairment, keep patients hydrated; discontinue use if persistent diarrhoea or colitis occur
Interactions
Neuromuscular blocking agents.
Pregnancy
Caution advised
Lactation
Not recommended.
Side Effects
Abdominal discomfort, anaphylactoid reactions, antibiotic-associated colitis, diarrhoea (discontinue treatment), eosinophilia, exfoliative dermatitis, jaundice, leucopenia, nausea, oesophageal ulcers, oesophagitis, polyarthritis, pruritus, rash, Stevens-Johnson syndrome, taste disturbances, thrombocytopenia, toxic epidermal necrolysis, urticaria, vesiculobullous dermatitis, vomiting